Rafał Kamiński

Ph.D., Angelini Pharma, Italy


Dr Rafal Kaminski has broad international experience in the discovery and development of innovative small-molecule drugs. After obtaining a medical degree and a doctorate in pharmacology at the Medical University of Lublin (Poland), he completed his post-doctoral training in the Netherlands (Radboud University) and USA (National Institutes of Health), as well as obtained the Diploma in Pharmaceutical Medicine (ULB, Belgium). He joined the pharmaceutical industry more than 15 years ago and worked at UCB Pharma (Belgium) and Roche (Switzerland). Dr Kaminski served as Chief Scientific Officer and Board Member of Molecure Therapeutics; a leading Polish biotech company listed on Warsaw Stock Exchange. At Molecure he was responsible for an integrated R&D organization, spanning from discovery to clinical development and was a key contributor to the licensing deal signed with Galapagos NV, which had the largest value on the Polish biotech scene at the time. Currently, Dr Kaminski is Chief Scientific Officer and Head of R&D at Angelini Pharma (Italy). He is also an Adjunct Scientist at the Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College. Three of his drug discovery projects successfully completed Phase I/II studies and one drug candidate entered Phase III clinical development. He also has experience in coordination and oversight of drug discovery projects performed in collaboration with academic partners. He was a member of scientific advisory boards and expert committees (FP7 UE; Wellcome Trust).  Dr Kaminski co-authored more than 100 scientific papers (including Nature group journals) and his publications were cited more than 4000 times. He is also an inventor in 7 patent applications.